Trial Profile
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2019
Price :
$35
*
At a glance
- Drugs GEN 003 (Primary) ; Matrix M
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Genocea Biosciences [CEASED]
- 29 Jan 2019 Status changed to discontinued.
- 20 Jul 2018 Status changed from active, no longer recruiting to completed.
- 21 Jul 2017 Status changed from recruiting to active, no longer recruiting.